JPMorgan Reiterates Overweight Rating on Mirati Therapeutics (MRTX)

Citi Downgrades Mirati Therapeutics (MRTX) to Neutral

Citi analyst Yigal Nochomovitz downgraded Mirati Therapeutics (NASDAQ: MRTX) from Buy to Neutral with a price target of $53.00 (from $121.00).

The analyst comments "We recognize MRTXs new meta-analysis suggests the bar in 1L G12C NSCLC is lower than we previously believed (wed cited a ~63-67%... More

Jefferies Reiterates Buy Rating on Mirati Therapeutics (MRTX)

Jefferies analyst Maury Raycroft reiterated a Buy rating and $149.00 price target on Mirati Therapeutics (NASDAQ: MRTX)

The analyst comments "Abstract data strengthen adagrasib's 1L pembro combo profile, removing worst-case scenarios and showing positive differentiation on safety+efficacy vs AMGN. MRTX said we'll... More

Piper Sandler Reiterates Overweight Rating on Mirati Therapeutics (MRTX)

Piper Sandler analyst Swapnil Malekar reiterated an Overweight rating and $110.00 price target on Mirati Therapeutics (NASDAQ: MRTX)

The analyst comments "ESMO-IO abstract revealed that adagrasib+pembro combo in 1L NSCLC patients showed an ORR of 49%, which came in below the Street expectation of ~55%... More

Morgan Stanley Reiterates Equalweight Rating on Mirati Therapeutics (MRTX)

Morgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $100.00 price target on Mirati Therapeutics (NASDAQ: MRTX)

The analyst comments "Data in the abstract from the Ph2 K-7 study (adagrasib + pembro) in 1L NSCLC confirm a tolerable safety profile, as expected. That... More

Zai Lab Partner Mirati Therapeutics (MRTX) Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic NSCLC

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the companys partner Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company reported preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the potential tolerability and feasibility of a concurrent combination regimen of a KRASG12C... More

Mirati Therapeutics (MRTX) phase 3 SAPPHIRE study to continue to final analysis

Mirati Therapeutics, Inc. (NASDAQ:... More